Filtered By:
Condition: Arrhythmia
Nutrition: Vitamins
This page shows you your search results in order of date.
Order by Relevance | Date
Total 249 results found since Jan 2013.
Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice
Biomed Pharmacother. 2023 Jun 21;165:115020. doi: 10.1016/j.biopha.2023.115020. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and in recent years the pharmacological approach has been strongly implemented; in Italy, the prescription of the non-vitamin K oral anticoagulants (NOAC) was also extended to General Practitioners (GPs) since 2020. The aim of the present study was to investigate the GPs prescribing behaviour of NOACs. An observational study was performed by using the computerized medical record of 14 GPs in Sicily: patients affected by AF were selected and st...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 23, 2023 Category: Drugs & Pharmacology Authors: M Rottura S F A Drago A Molonia N Irrera S Marino R Scoglio L Orlando M Gigliotti De Fazio F Squadrito V Arcoraci E Imbalzano on the behalf of Audit & Research Messina Primary Care Group Source Type: research
Racial and Ethnic Disparities in Stroke Prevention for Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting around 2% of the population (1,2) and increasing the risk of stroke by 4 to 5 times (3). Anticoagulation with Vitamin K antagonists (VKAs) such as Warfarin (4) or the newer Direct Oral Anticoagulants (DOACs) (4,5) reduces this risk by up to 60%. AF-related strokes also tend to be more severe and disabling (6).
Source: The American Journal of Medicine - December 7, 2022 Category: General Medicine Authors: Peter Calvert, Kamala Tamirisa, Amin Al-Ahmad, Gregory Y H Lip, Dhiraj Gupta Tags: Review Source Type: research
Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: A current overview
J Cardiol. 2022 Nov 15:S0914-5087(22)00277-5. doi: 10.1016/j.jjcc.2022.11.006. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF causes palpitations, heart failure, and cardiogenic embolism. Of them, the most critical and fatal complication is a cardio-embolic event. Oral anticoagulation plays a central role in reducing stroke risk in AF patients. Recently, when oral anticoagulation is considered in patients with non-valvular AF who are eligible for direct oral coagulations, they are preferred to vitamin K antagoni...
Source: Journal of Cardiology - November 18, 2022 Category: Cardiology Authors: Hiroshi Ueno Teruhiko Imamura Shuhei Tanaka Nobuyuki Fukuda Koichiro Kinugawa Source Type: research
Comparison of Dabigatran Versus Warfarin Treatment for the Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation
Atrial fibrillation is one of the most common arrhythmias in the United States and is associated with an increased risk of thromboembolic events.1 The American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines recommend oral anticoagulation with either warfarin or oral non-vitamin K antagonists for patients diagnosed with atrial fibrillation with a high risk for ischemic stroke based on the CHA2DS2-VASc score.2 The recently published article “Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation” discussed the efficacy of...
Source: The American Journal of Cardiology - October 7, 2022 Category: Cardiology Authors: Marwa S.H. Abrahim, Olufemi Sofola-James, Zeina Bani Hani Source Type: research
The great discovery of DOACs and why physicians insist on misusing it: A paradox of the 21 century
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and has been one of the most studied disease in the world for the last 20 years. As it is a frequent cause of preventable strokes, substantial research efforts were directed toward gaining detailed information about effective prophylactic treatments. New evidence has been continuously published and resulted in the approval of direct-acting oral anticoagulants (DOACs) i n this scenario, which are safer and easier to use than vitamin K antagonists (VKA).[1]Although the randomized clinical trials that substantiated the approval of DOACs were based in ...
Source: International Journal of Cardiology - June 1, 2022 Category: Cardiology Authors: Fl ávia Bittar B. Arantes, Remo H.M. Furtado Tags: Editorial Source Type: research
Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
ConclusionsEarly AF ablation in a contemporary prospective cohort of AF patients who were predominantly treated with NOACs was associated with a survival advantage compared to medical therapy alone.Trial registrationClinical trial registration:http://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007 and NCT01937377.Graphical abstractCreated with BioRender.com.
Source: Clinical Research in Cardiology - April 29, 2022 Category: Cardiology Source Type: research
Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society
ConclusionsSignificant progress has been made within the past 2 decades both in the pharmacological and non-pharmacological managements of this cardiac arrhythmia.
Source: Journal of Interventional Cardiac Electrophysiology - April 13, 2022 Category: Cardiology Source Type: research
Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia
Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, which is associated with an increased risk of thromboembolism, heart failure and mortality.1 Previous studies in atrial fibrillation patients have reported that abnormal hemoglobin and platelet counts may be associated with adverse events. However, these studies that specifically examined the associations between hemoglobin and platelet levels and adverse outcomes reported conflicting data.2-5 Although warfarin effectively reduces the risk of ischemic stroke by 64% compared to placebo/control,6 and non-vitamin K antagonist oral antico...
Source: The American Journal of Medicine - April 2, 2022 Category: General Medicine Authors: Yung-Hsin Yeh, Yi-Hsin Chan, Shao-Wei Chen, Shang-Hung Chang, Chun-Li Wang, Chi-Tai Kuo, Gregory Y.H. Li, Shih-Ann Chen, Tze-Fan Chao Tags: Clinical Research Study Source Type: research
